February 2, 2023
Via: Biopharma DiveJesduvroq belongs to a new class of oral treatments that GSK, along with rivals FibroGen and Akebia Therapeutics, saw as more convenient alternatives to the injectable medicines that are currently standard for treating kidney disease-related anemia. But in August 2021 […]
July 19, 2024
July 11, 2024
July 11, 2024